Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04521699 · ClinicalTrials.gov registry record · NA

Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

A NA study of Myocardial Infarction, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT04521699 is a NA study of Myocardial Infarction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 4,680-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04521699, a NA study of Myocardial Infarction, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.

Conditions Studied

Interventions

  • DEVICE CalmioGO Stress management device

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-01-13
Est. Completion 2026-12
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04521699

The ClinicalTrials.gov registry entry for NCT04521699 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,680-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which CalmioGO Stress management device is the first listed.

NCT04521699 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04521699 about?

NCT04521699 is a clinical study titled "Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.". The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.

What is the current status of trial NCT04521699?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-01-13. Estimated completion is 2026-12.

What conditions does trial NCT04521699 study?

This clinical trial studies the following conditions: Myocardial Infarction.

What interventions are being tested in trial NCT04521699?

The interventions under investigation include: CalmioGO Stress management device (DEVICE).

Who is sponsoring clinical trial NCT04521699?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04521699 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.